Welcome Dr. Shayna Sarosiek!
We are pleased to announce the addition of Dr. Shayna Sarosiek to the Bing Center for Waldenstrom's Macroglobulinemia.
Prior to joining the Bing Center, Dr. Sarosiek completed her Internal Medicine residency, as well as her Amyloidosis and Hematology/Oncology Fellowship at Boston University Medical Center. After completing her training she remained as a faculty member at Boston University for 4 years. During that time she worked as a hematologist treating patients with benign and malignant hematologic issues, such as monoclonal gammopathy of undetermined significance (MGUS), lymphoma, WM, and multiple myeloma. She focused the majority of her research efforts on plasma cell disorders, including MGUS, multiple myeloma and amyloidosis. She also actively participated in the care of patients at the Boston University Amyloidosis Center and has published many original research articles in that field. She is looking forward to using the expertise she gained at that center to improve the care of patients with WM and AL amyloidosis.
In the Bing Center Dr. Sarosiek will be joining Dr. Jorge Castillo in the clinic to see patients and help care for the constantly increasing number of Waldenstrom patients at our center. She will also be actively involved in clinical research and will focus her research efforts on the use of immunotherapies and antibody treatments in WM, as well as developing therapies and caring for those patients who have both WM and AL amyloidosis.
Please join us in welcoming Dr. Sarosiek to the Bing Center!
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Great Debates in Hematological Malignancies - 2021
We're pleased to announce that registration is now open for the 2021 Great Debates & Updates Conferences. Each meeting will cover the most critical updates occurring in the field, while incorporating a distinct focus on the latest advances and treatment options.
A WMer's thoughts around the holidays from her to you....
Thanksgiving 2020: Home, but not Alone: Has your sense of time shifted lately? Does avoiding people feel bizarre, and has Purell become your new best friend? Do you spot beauty in surprising places, and feel the rhythm of your breath inside your mask?
Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia
On October 21, 2020, Dr. Steven Treon gave a webcast lecture to the Canadian National WMFC Patient Support Group. The main topic was genomic & treatment advances in WM, with the discussion also including the related issues surrounding COVID-19.
Treatment Advancements are Improving Survivorship and Prompting Hope
Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach? Patient Power Co-Founder Andrew Schorr speaks with Dr. Steven Treon, director, Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, about his predictions for the future of Waldenstrom macroglobulinemia treatment.
IMS Virtual Workshop November 6-7, 2020
Dr. Steven Treon will be giving a lecture on "New Insights into Waldenstrom's in Session 4 of this virtual Workshop. If you are interested in attending, registration will be closing soon.
Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020
The Eastern Massachusetts IWMF Support Group invites WM/Bing-Neel patients and caregivers from across the globe to join us in the first-ever support group meeting focused on this particularly rare WM complication. With Bing-Neel specialists, Dr. Steve Treon and Dr. Jorge Castillo of Dana-Farber Cancer Institute.
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Every two years WM experts from around the world meet to discuss the latest research and developments. The last meeting, IWWM-10 was held in New York in October, 2018, and the consensus recommendations on treatment have just been published in The Lancet. Registration (to read the article) is free.
Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM
Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).
The fourth issue of the 21st volume of the IWMF Torch is now online!
If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.
BTK Inhibitors Transform Waldenström Macroglobulinemia Management
BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.